Literature DB >> 17628772

[Molecular high throughput research in prostate carcinoma].

T Schlomm1, H Sültmann, A Poustka, G Sauter, O J C Hellwinkel, H Huland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17628772     DOI： 10.1007/s00120-007-1440-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  10 in total

1.  Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle.

Authors:  Dorit Arlt; Wolfgang Huber; Urban Liebel; Christian Schmidt; Meher Majety; Mamatha Sauermann; Heiko Rosenfelder; Stephanie Bechtel; Alexander Mehrle; Detlev Bannasch; Ingo Schupp; Markus Seiler; Jeremy C Simpson; Florian Hahne; Petra Moosmayer; Markus Ruschhaupt; Birgit Guilleaume; Ruth Wellenreuther; Rainer Pepperkok; Holger Sültmann; Annemarie Poustka; Stefan Wiemann
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 2.  Targeting HER2 in other tumor types.

Authors:  S Scholl; P Beuzeboc; P Pouillart
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

Review 3.  Molecular staging of prostate cancer in the year 2007.

Authors:  Thorsten Schlomm; Andreas Erbersdobler; Martina Mirlacher; Guido Sauter
Journal:  World J Urol       Date:  2007-03-02       Impact factor: 4.226

4.  Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis.

Authors:  Thorsten Schlomm; Andreas M Luebke; Holger Sültmann; Olaf J C Hellwinkel; Ulrich Sauer; Annemarie Poustka; Kerstin A David; Felix K H Chun; Alexander Haese; Markus Graefen; Andreas Erbersdobler; Hartwig Huland
Journal:  Int J Oncol       Date:  2005-09       Impact factor: 5.650

5.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.

Authors:  Thorsten Schlomm; Patrick Kirstein; Liv Iwers; Birte Daniel; Thomas Steuber; Jochen Walz; Felix H K Chun; Alexander Haese; Jens Kollermann; Markus Graefen; Hartwig Huland; Guido Sauter; Ronald Simon; Andreas Erbersdobler
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

8.  Close association between HER-2 amplification and overexpression in human tumors of non-breast origin.

Authors:  Coya Tapia; Katharina Glatz; Hedvika Novotny; Alessandro Lugli; Milo Horcic; Christian A Seemayer; Luigi Tornillo; Luigi Terracciano; Hanspeter Spichtin; Martina Mirlacher; Ronald Simon; Guido Sauter
Journal:  Mod Pathol       Date:  2007-02       Impact factor: 7.842

9.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Authors:  Frederik Holst; Phillip R Stahl; Christian Ruiz; Olaf Hellwinkel; Zeenath Jehan; Marc Wendland; Annette Lebeau; Luigi Terracciano; Khawla Al-Kuraya; Fritz Jänicke; Guido Sauter; Ronald Simon
Journal:  Nat Genet       Date:  2007-04-08       Impact factor: 38.330

10.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440
  10 in total
  2 in total

1.  [Identification and validation of clinically relevant molecular alterations in prostate cancer].

Authors:  T Schlomm; H Sültmann; J Köllermann
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

2.  [Identification and validation of clinically relevant molecular alterations in prostate cancer].

Authors:  T Schlomm; H Sültmann; J Köllermann
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.